Literature DB >> 18449519

[Experimental treatment of malignant melanoma and its rationale].

K Rass1, M Diefenbacher, W Tilgen.   

Abstract

To treat malignant melanoma successfully currently means to recognize the tumor at an early stage and to remove it immediately. Aside from individual cases, available treatment modalities are not able to increase survival, especially in the palliative situation. Thus innovative experimental approaches are urgently needed to strongly improve the palliative and adjuvant treatment of melanoma. Anti-tumor effects are expected from targeted therapies, which are directed against defined molecules decisive for tumor pathogenesis. Crucial points of attack are signaling pathways, angiogenesis and apoptosis resistance. New diagnostic and therapeutic developments have enhanced the efficacy of chemotherapies. Increasing insights into tumor immunology provide new treatment approaches of vaccination, cell transfer and especially of blocking immune tolerance mechanisms. It will be challenging for the future to identify and characterize more precisely those patients who might most benefit from a certain treatment approach.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18449519     DOI: 10.1007/s00105-008-1556-5

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  34 in total

Review 1.  The RTK/RAS/BRAF/PI3K pathways in melanoma: biology, small molecule inhibitors, and potential applications.

Authors:  Frank Haluska; Trevor Pemberton; Nageatte Ibrahim; Kevin Kalinsky
Journal:  Semin Oncol       Date:  2007-12       Impact factor: 4.929

2.  More support for the judicious use of high-dose interleukin-2 in patients with advanced melanoma.

Authors:  David F McDermott; Michael B Atkins
Journal:  J Clin Oncol       Date:  2007-09-01       Impact factor: 44.544

3.  Distinct sets of genetic alterations in melanoma.

Authors:  John A Curtin; Jane Fridlyand; Toshiro Kageshita; Hetal N Patel; Klaus J Busam; Heinz Kutzner; Kwang-Hyun Cho; Setsuya Aiba; Eva-Bettina Bröcker; Philip E LeBoit; Dan Pinkel; Boris C Bastian
Journal:  N Engl J Med       Date:  2005-11-17       Impact factor: 91.245

4.  Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen.

Authors:  M J Maeurer; S M Gollin; D Martin; W Swaney; J Bryant; C Castelli; P Robbins; G Parmiani; W J Storkus; M T Lotze
Journal:  J Clin Invest       Date:  1996-10-01       Impact factor: 14.808

Review 5.  Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies.

Authors:  Steven J O'Day; Omid Hamid; Walter J Urba
Journal:  Cancer       Date:  2007-12-15       Impact factor: 6.860

6.  Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2.

Authors:  J J Mulé; S Shu; S L Schwarz; S A Rosenberg
Journal:  Science       Date:  1984-09-28       Impact factor: 47.728

Review 7.  [Therapy of malignant melanoma at the stage of distant metastasis].

Authors:  C Garbe; T K Eigentler
Journal:  Hautarzt       Date:  2004-02       Impact factor: 0.751

Review 8.  Adoptive cell transfer therapy.

Authors:  Mark E Dudley; Steven A Rosenberg
Journal:  Semin Oncol       Date:  2007-12       Impact factor: 4.929

9.  Mutations of the BRAF gene in human cancer.

Authors:  Helen Davies; Graham R Bignell; Charles Cox; Philip Stephens; Sarah Edkins; Sheila Clegg; Jon Teague; Hayley Woffendin; Mathew J Garnett; William Bottomley; Neil Davis; Ed Dicks; Rebecca Ewing; Yvonne Floyd; Kristian Gray; Sarah Hall; Rachel Hawes; Jaime Hughes; Vivian Kosmidou; Andrew Menzies; Catherine Mould; Adrian Parker; Claire Stevens; Stephen Watt; Steven Hooper; Rebecca Wilson; Hiran Jayatilake; Barry A Gusterson; Colin Cooper; Janet Shipley; Darren Hargrave; Katherine Pritchard-Jones; Norman Maitland; Georgia Chenevix-Trench; Gregory J Riggins; Darell D Bigner; Giuseppe Palmieri; Antonio Cossu; Adrienne Flanagan; Andrew Nicholson; Judy W C Ho; Suet Y Leung; Siu T Yuen; Barbara L Weber; Hilliard F Seigler; Timothy L Darrow; Hugh Paterson; Richard Marais; Christopher J Marshall; Richard Wooster; Michael R Stratton; P Andrew Futreal
Journal:  Nature       Date:  2002-06-09       Impact factor: 49.962

10.  BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.

Authors:  Scott M Wilhelm; Christopher Carter; Liya Tang; Dean Wilkie; Angela McNabola; Hong Rong; Charles Chen; Xiaomei Zhang; Patrick Vincent; Mark McHugh; Yichen Cao; Jaleel Shujath; Susan Gawlak; Deepa Eveleigh; Bruce Rowley; Li Liu; Lila Adnane; Mark Lynch; Daniel Auclair; Ian Taylor; Rich Gedrich; Andrei Voznesensky; Bernd Riedl; Leonard E Post; Gideon Bollag; Pamela A Trail
Journal:  Cancer Res       Date:  2004-10-01       Impact factor: 13.312

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.